Somaxon Settles IP Rows With Mylan, Par Over Insomnia Drug

By Linda Chiem (July 18, 2012, 6:43 PM EDT) -- Somaxon Pharmaceutical Inc. said Tuesday it had settled patent infringement suits against generic drugmakers Mylan Inc. and Par Pharmaceutical Cos. Inc., striking deals that will keep generic versions of Somaxon's insomnia treatment drug from hitting the U.S. market until 2020....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!